According to Fact.MR, a provider of market research and competitive intelligence, Americas hospital acquired infection testing market was estimated to be worth US$ 595 million in 2020 and is anticipated to grow at a compound annual growth rate (CAGR) of about 15% between 2021 and 2031.
The risk of acquiring surgical site infections is increasing due to an increase in surgical procedures. In both industrialized and developing nations, surgical site infections (SSIs) are the most often reported surgical complication and healthcare-acquired illness.
Hospital acquired infections (HAIs) are more common in infants, the elderly, and those with compromised immune systems. Numerous conventional antibiotics are ineffective against a variety of hospital-associated pathogens. The widespread use of antibiotics in hospitals encourages the growth of microorganisms that are resistant to them. Commonly acquired hospital infections include bacterial infections, pneumonia, lung infections, surgical site infections, and urinary tract infections (UTI).
For More Insights on this Market, Get A Sample Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=6592
According to the Centers for Disease Control and Prevention (CDC), HAIs affect 1.7 million patients in hospitals across the Americas alone, resulting in 99,000 deaths per year. The high death rate and related economic burden have prompted healthcare practitioners to devise an effective technique to reduce infection rates.
When releasing novel tests or kits to the market, service providers confront a variety of challenges. One of these is strict government rules. Diagnostic kits created by independent medical device makers and marketed to medical laboratories are subject to stringent regulatory requirements and a lengthy FDA clearance process.
Country-wise Insights:
How Lucrative is the Opportunity for Hospital-Acquired Infection Testing Kit Manufacturers in the U.S.?
The U.S. is projected to hold nearly 58% of the market share in 2021, making it the largest regional market for HAI testing in the Americas. The demand for HAI testing kits is driven by longer hospital stays and the increased risk of developing infections.
Furthermore, heightened awareness around reducing hospital readmission rates through various programs and a strong emphasis on minimizing the economic impact of HAIs present valuable growth opportunities in the U.S. market.
What are the Key Factors Driving the Growth of Hospital-Acquired Infection Testing in Brazil?
Brazil held over 32% of the Latin American market share in 2020. The gradual improvements in the country’s healthcare sector over the past decade have played a key role in the market's expansion.
Additionally, the growing patient population and the rise in medical tourism in Brazil are contributing significantly to the increased demand for HAI testing kits.
What is the Growth Potential for Hospital-Acquired Infection Testing in Mexico?
The HAI testing market in Mexico is expected to grow at a robust rate of over 20% CAGR and account for nearly 28% of the Latin American HAI diagnostics market.
Emerging economies like Mexico have significant growth potential, primarily due to ongoing improvements in healthcare infrastructure and an increasing need for effective HAI prevention.
Category-wise Insights:
What is the Growth Potential for Home Care Testing for Hospital-Acquired Infections?
While diagnostic laboratories currently hold a 35.8% market share, home care testing for hospital-acquired infection (HAI) control is expected to experience significant growth, with a projected CAGR of 23%.
The growing demand for point-of-care testing, which offers rapid and accurate results with quick turnaround times, is a major factor driving the adoption of home care testing for HAIs. Other contributing factors include the increasing aging population requiring healthcare services, specimen stability, ease of handling, fewer unnecessary hospital visits, and improved patient outcomes.
What Impact Did COVID-19 Have on Hospital-Acquired Infection Testing in the Americas?
The COVID-19 pandemic is anticipated to have a moderately positive effect on the growth of the Americas’ HAI testing market. Technological advancements have led to a preference for point-of-care testing over traditional methods, boosting the demand for point-of-care testing kits during the pandemic.
Segments as per Americas Hospital Acquired Infection Testing Industry Research
-
By Test
- MSRA Testing Kits
- MRSA Real-Time PCR Detection Kits
- MRSA Rapid Test Kits
- Staphylococcus aureus Detection Kits
- Staphylococcus aureus Latex Test Kits
- Staphylococcus aureus Assay Test Kits
- Clostridium difficile Testing Kits
- Clostridium difficile Detection Panels
- Clostridium difficile Immunoassay Kits
- Helicobacter pylori Testing Kits
- Helicobacter pylori Rapid Antigen Test Kits
- Helicobacter pylori IgG antibodies Test Kits
- Rotavirus/ Adenovirus Real-time PCR Kits
- RSV RT-PCR Test Kit
- RSV Ag Rapid Test Kits
- Strep A Rapid Testing Kits
- Strep B Rapid Testing Kits
- Mononucleosis Testing Kits
- Calprotectin Test Kits
- MSRA Testing Kits
-
Modality
- Immunoassay Testing
- Point-of-care Testing
-
By Sample
- Blood
- Nasal Swabs
- Urine
- Stool
-
By End User
- Hospitals
- Diagnostic Laboratories
- Cancer Research Institutes
- Specialty Clinics
- Home Care Settings
𝐂𝐨𝐧𝐭𝐚𝐜𝐭:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
Comments
0 comment